Product Description
Mechanisms of Action: PR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Vaginal
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Brazil | Chile | Ireland | Italy | Peru | Portugal | Sweden
Approved Indications: None
Known Adverse Events: None
Company: Evestra
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Menopause
Phase 2: Contraception
Phase 1: Pregnancy Outcomes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Ovulation inhibition study with trimegestone | P2 |
Completed |
Contraception |
2019-04-05 |
2022-03-13 |
Treatments |
|
| GDN 012/17 | P1 |
Completed |
Pregnancy Outcomes |
2018-01-12 |
2020-05-08 |
Primary Endpoints|Treatments|Trial Status |
|
| 0753T-101538 | P4 |
Completed |
Menopause |
None |
2019-03-21 |
Treatments |